Abstract
Subjective cognitive decline (SCD) is a high-risk yet less understood status years before Alzheimer’s disease (AD). This work included 76 SCD individuals with two (baseline and seven years later) neuropsychological evaluations and a baseline T1-MRI. A machine learning-based model was trained based on 198 baseline neuroimage features and a battery of 25 clinical measurements to discriminate 24 progressive SCDs from 52 stable SCDs. The SCD progression was satisfactorily predicted with combined features. A history of stroke, a low education level, a low baseline MoCA score, a shrunk left amygdala, and enlarged white matter at the banks of the right superior temporal sulcus favor the progression. This is to date the largest retrospective study of SCD-to-MCI conversion with the longest follow-up, suggesting predictable far-future cognitive decline for the risky populations with baseline measures only. These findings provide valuable knowledge to the future neuropathological studies of AD in its prodromal phase.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03672448
Funding Statement
This work was supported by the China Ministry of Science and Technology (2009BAI77B03), Shanghai Mental Health Center (CRC2017ZD02, 2018-FX-05), Shanghai Clinical Research Center for Mental Health (SCRC-MH, 19MC1911100), the National Natural Science Foundation of China (81830059), Shanghai Jiaotong University School of Medicine (CBXJ201815, YG2016MS38), and Shanghai Municipal Human Resources Development Program (2017BR054).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Imaging and clinical data as well as the computing code used in the current manuscript are available from the corresponding authors upon request from any qualified investigator.